Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold shares valued at approximately $3.65 million. These sales were conducted at prices ranging from $362.71 to $369.19 per share. The transaction comes as the company maintains excellent financial health according to InvestingPro analysis, with impressive gross profit margins of 89% and a strong 70% stock return over the past year.
In addition to the sales, Benkowitz also exercised stock options, acquiring 10,000 shares at a price of $111.00 each. The transactions were conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell company stock in order to avoid any potential accusations of insider trading. The shares were held in a trust that Benkowitz beneficially owns, with shared investment and voting power between him and his spouse. Trading near its Fair Value, UTHR currently maintains a modest P/E ratio of 15.4. For deeper insights into insider trading patterns and 12+ additional ProTips, explore InvestingPro's comprehensive research reports.
In other recent news, United Therapeutics Corporation reported a significant increase in its third-quarter revenue for 2024, reaching $749 million, a 23% increase from the same period last year. This growth was largely driven by the company's key products: Tyvaso, Orenitram, and Unituxin. The company also completed a $1 billion accelerated share repurchase program. Analysts at H.C. Wainwright reaffirmed a Buy rating on the company, citing strategic positioning and proactive measures such as initiating contracts with Part D payers. The firm also increased the price target for United Therapeutics to $425 from the previous $400, reflecting a positive outlook on Tyvaso's performance.
In other recent developments, United Therapeutics announced the successful transplantation of a gene-edited pig kidney, called UKidney, into a human patient. The company, which has achieved a remarkable 25% revenue growth over the last twelve months and maintains strong financial health, is preparing an investigational new drug application (IND) for the UKidney, with plans to initiate a human clinical study in 2025, pending FDA clearance.
TD Cowen, through its analyst Joseph Thome, outlined ten anticipated catalysts for the year 2025 that are expected to generate significant investor interest. ANAB is expected to release Phase II rheumatoid arthritis data for Rosnilimab, and UTHR is looking to extend the success of its Tyvaso treatment to a Phase III idiopathic pulmonary fibrosis program. Meanwhile, QURE is working towards submitting an accelerated approval application for AMT-130 in Huntington's disease. The company maintains a healthy liquidity position with a current ratio of 6.51. These are recent developments and investors should keep an eye on these events.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.